Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX-410 + Pembrolizumab + Chemotherapy in Metastatic TNBC
NCT04634747Phase 2Unknown
- Sponsor
- OncoPep
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
01
Overview
A Phase 2 trial of pvx-410 in triple-negative breast cancer (TNBC), sponsored by OncoPep. Status: unknown.
02
Drugs
pvx-410
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04634747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634747.